bs-9865R-Cy7 [Conjugated Primary Antibody]
MYLK3 Polyclonal Antibody, Cy7 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: MYLK3

Immunogen Range: 701-800/817


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human MYLK3

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The Ca2+/calmodulin-dependent protein kinases (CaM kinases) are a structurally related subfamily of serine/threonine kinases that includes CaMKI, CaMKII, CaMKIV and Myosin light chain kinases (MYLKs, also designated MLCKs). The MYLK kinases phosphorylate Myosin regulatory light chains to catalyze Myosin interaction with Actin filaments, resulting in contractile activity. MYLK3 (Myosin light chain kinase 3) is a 795 amino acid cardiac-specific protein that contains one protein kinase domain and belongs to the protein kinase superfamily. Like other MYLK kinases, MYLK3 is thought to play a role in smooth muscle contraction, specifically using magnesium as a cofactor to catalyze the ATP-dependent phosphorylation of Myosin light chain proteins. Additionally, MYLK3 may regulate sarcomere assembly in heart tissue, possibly mediating proper heart function.

Conjugation: Cy7

Excitation/ Emission: 743nm/767nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Hu S et al. Down‐regulation of miR‐200c attenuates AngII‐induced cardiac hypertrophy via targeting the MLCK‐mediated pathway.  Cell Mol Med. 2019 Apr;23(4):2505-2516Read more>>
VALIDATION IMAGES